616 related articles for article (PubMed ID: 19565495)
1. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
[TBL] [Abstract][Full Text] [Related]
2. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.
Lanternier F; Tubach F; Ravaud P; Salmon D; Dellamonica P; Bretagne S; Couret M; Bouvard B; Debandt M; Gueit I; Gendre JP; Leone J; Nicolas N; Che D; Mariette X; Lortholary O;
Chest; 2013 Sep; 144(3):990-998. PubMed ID: 23744173
[TBL] [Abstract][Full Text] [Related]
4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
5. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.
Lee SK; Kim SY; Kim EY; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA
Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990
[TBL] [Abstract][Full Text] [Related]
7. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
8. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
[TBL] [Abstract][Full Text] [Related]
10. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
[TBL] [Abstract][Full Text] [Related]
11. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
12. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers.
Kim EM; Uhm WS; Bae SC; Yoo DH; Kim TH
J Rheumatol; 2011 Oct; 38(10):2218-23. PubMed ID: 21844149
[TBL] [Abstract][Full Text] [Related]
13. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
14. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
15. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
17. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
18. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
19. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
20. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.
Curtis JR; Xie F; Chen L; Muntner P; Grijalva CG; Spettell C; Fernandes J; McMahan RM; Baddley JW; Saag KG; Beukelman T; Delzell E
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1480-9. PubMed ID: 22833479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
